Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a CT scan replace PET for heart disease diagnosis?

NCT ID NCT04316676

Diagnosis Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two types of heart scans—CT and PET—to see if CT can measure blood flow to the heart as accurately as PET, which is the current gold standard. Researchers enrolled 20 adults with suspected coronary artery disease. Each participant received both a CT scan and a PET scan, and the results were compared. The goal was to determine if CT could be a reliable alternative for diagnosing blockages in heart arteries.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that CT scans are as good as PET scans for diagnosing heart artery disease, potentially offering a faster, cheaper, and more widely available diagnostic option.
What could go wrong
This was a small study with only 20 participants, so results may not apply to everyone. It compared imaging methods, not treatments, so it won't directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jun 2021

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Referred for a clinically indicated CT-MPI for CAD assessment * Must provide written informed consent prior to any study-related procedures being performed * Must be willing to comply with all clinical study procedures Exclusion Criteria: * Pregnant or nursing females. The possibility of pregnancy will be excluded by testing (serum or urine ßHCG) within 24 hours before study agent administration, or if the woman has previous surgical sterilization, or if the woman is post-menopausal, with minimum one (1) year history without menses. * Currently taking or has taken within 48 hours the following excluded medications: * ActoPlus Met (Pioglitazone + metformin) * Avandamet (Rosiglitazone + metformin) * Fortamet (metformin) * Glucovance (Glyburide +metformin) * Glucophage (metformin) * Glucophage extended-release (XR) (metformin) * Glumetza (metformin) * Janumet (Sitagliptin + metformin) * Metformin * Metaglip (Glipizide + metformin) * Riomet (metformin) * Acute psychiatric disorder * Unwilling to comply with the requirements of the protocol * Previously entered this study * Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study * Suffers from claustrophobia * Impaired renal function (GFR \< 45 ml/min) * Acute hypotension (\<100 mm Hg systolic) * 2nd or 3rd degree atrioventricular (AV) block

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular disorder coronary artery disorder myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

Contacts and locations

Locations

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.